Clinical Information for Insulin Glargine Dosing

A guide to the principles, calculations, and safety considerations for initiating insulin glargine in adults with diabetes.

About

This information supports the use of an Insulin Glargine Starting Dose Calculator, a tool designed to estimate initial daily doses of this long-acting basal insulin. Insulin glargine (available as U-100 and U-300 formulations) provides a steady, peakless level of insulin over approximately 24 hours, helping to control blood glucose between meals and overnight.

Outputs

The calculator provides starting dose recommendations based on patient type and clinical scenario:

  • Type 1 Diabetes: The starting dose is calculated based on body weight, typically representing 50% of the total daily insulin (TDD) requirement (e.g., 0.4 units/kg TDD). The other 50% should be covered by rapid-acting insulin at mealtimes.
  • Type 2 Diabetes (Insulin-Naïve): The calculator presents two common starting strategies for clinician consideration: a fixed dose of 10 units daily or a weight-based dose of 0.2 units/kg daily.
  • Type 2 Diabetes (Switching): The dose is calculated based on the previous insulin regimen, often involving a dose adjustment to ensure safety. For example, switching from twice-daily NPH insulin typically requires a 20% reduction in the total daily dose.
  • Safety Flags: The tool highlights when a more conservative approach is needed due to factors like advanced age, frailty, or significant renal/hepatic impairment.

How to Use

To use the accompanying calculator, a clinician would input the following key patient data:

  • Diabetes Type: Select Type 1 or Type 2.
  • Patient Weight: Enter weight in kilograms (kg) or pounds (lbs).
  • Glargine Formulation: Choose between U-100 (e.g., Lantus®, Basaglar®) or U-300 (e.g., Toujeo®).
  • Insulin Status (for Type 2): Specify if the patient is insulin-naïve or switching from another insulin.
  • Previous Regimen Details (if switching): Select the previous insulin type and enter its total daily dose in units.
  • Clinical Considerations: Check boxes for elderly/frail status or significant organ impairment to receive relevant safety warnings.

Dosing Overview

Insulin glargine is a basal insulin administered subcutaneously once daily, at the same time each day. The goal of initiation is to establish a safe and effective starting dose that can be titrated to achieve glycemic targets.

Initiation

For patients with type 2 diabetes not previously on insulin, a common starting dose is 10 units once daily or 0.1-0.2 units/kg once daily. The dose must be individualized based on the patient's metabolic needs, blood glucose monitoring data, and glycemic goals.

Titration

After initiation, the dose should be adjusted based on the patient's fasting plasma glucose (FPG) levels. A typical titration schedule involves increasing the dose by 2-4 units every 3-7 days until the target FPG is consistently achieved without hypoglycemia.

Switching

When transitioning a patient to insulin glargine from another insulin product, specific conversion rules apply to minimize the risk of hypo- or hyperglycemia:

  • From another once-daily basal insulin: A 1:1 unit conversion is typically recommended (e.g., 25 units of insulin detemir becomes 25 units of insulin glargine).
  • From twice-daily NPH insulin: The recommended starting dose of insulin glargine is 80% of the total daily NPH dose (e.g., 20 units of NPH twice daily = 40 units TDD; start glargine at 32 units).
  • From pre-mixed insulin: The starting dose is often calculated as 80% of the basal component of the pre-mixed insulin. If the basal component is 50% of the mix, this equates to 40% of the total daily pre-mixed dose.

Missed Dose

If a dose of insulin glargine is missed, patients should be advised to take it as soon as they remember. However, if it is almost time for the next scheduled dose, they should skip the missed dose and resume their regular dosing schedule. They should never take two doses at once to make up for a missed one. Blood glucose should be monitored more frequently after a missed dose.

Safety Alerts

Hypoglycemia is the most common adverse effect of all insulins, including insulin glargine. Symptoms may include shakiness, dizziness, sweating, confusion, and headache. Severe hypoglycemia can be life-threatening.

High-Risk Populations

A lower starting dose, more conservative titration, and increased monitoring are crucial for patients who are elderly, frail, or have significant renal or hepatic impairment, as their risk of hypoglycemia is higher.

Formulation Errors

Insulin glargine is available in different concentrations (U-100 and U-300). U-300 (Toujeo®) is three times more concentrated than U-100 (Lantus®, Basaglar®). A dose conversion may be necessary when switching between them, and extra care must be taken to ensure the patient uses the correct delivery device and understands the dose prescribed. Never use a U-100 syringe with U-300 insulin.

Frequently Asked Questions

Why are there two starting dose options for insulin-naïve Type 2 patients?

Clinical guidelines, such as those from the American Diabetes Association (ADA), support both a simple fixed starting dose (10 units) and a weight-based dose (0.1-0.2 units/kg). The fixed dose is simple to implement, while the weight-based approach provides a more personalized initial dose. Both are considered safe and effective starting points for titration.

Why is the dose reduced when switching from NPH insulin?

NPH insulin has a more pronounced peak effect compared to the flatter profile of insulin glargine. The 20% dose reduction is a conservative safety measure to mitigate the risk of hypoglycemia during the transition period as the body adjusts to the new insulin's pharmacokinetic profile.

What is the main difference between Glargine U-100 and U-300?

Glargine U-300 (e.g., Toujeo®) is three times as concentrated as U-100 (e.g., Lantus®). This higher concentration results in a smaller injection volume, a longer duration of action, and a flatter, more prolonged pharmacodynamic profile, which may lead to a lower risk of hypoglycemia compared to U-100 in some studies.

Can the daily dose of insulin glargine be split?

Insulin glargine is approved for once-daily administration. While splitting the dose is not standard practice and is considered off-label, some clinicians may do so in specific situations where a patient experiences waning effects before 24 hours. This should only be done under the direct guidance of a healthcare provider.

What is the maximum starting dose of insulin glargine?

There is no defined maximum starting dose, as it is based on individual factors like weight and prior insulin requirements. However, initiation should always be guided by clinical judgment, and high initial doses require close monitoring. The principle is to "start low and go slow" with titration.

Does renal impairment affect insulin glargine dosing?

Yes. Patients with significant renal (kidney) impairment may have reduced insulin clearance, which increases the duration of insulin action and elevates the risk of hypoglycemia. A lower starting dose and more cautious titration are strongly recommended in this population.

How long does it take for insulin glargine to start working?

Insulin glargine has a gradual onset of action, typically beginning within a few hours of injection. It does not have a pronounced peak and provides a relatively stable level of insulin over approximately 24 hours.

Why doesn't the calculator give a final, titrated dose?

The tool is designed only to calculate a safe *starting* dose. The final maintenance dose is highly individual and must be determined through a process of titration, where the dose is adjusted over days and weeks based on regular blood glucose monitoring and the patient's specific glycemic target.

References

PRO
Ad-Free Access
$3.99 / month
  • ✓ No Interruptions
  • ✓ Faster Page Loads
  • ✓ Support Content Creators
Subscribe Now